Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

Targeted cancer therapies exploit the continued dependence of cancer cells on oncogenic mutations. Such agents can have remarkable activity against some cancers, although antitumor responses are often heterogeneous, and resistance remains a clinical problem. To gain insight into factors that influen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wendel, Hans-Guido, de Stanchina, Elisa, Cepero, Enriqué, Ray, Sagarika, Emig, Michael, Fridman, Jordan S., Veach, Darren R., Bornmann, William G., Clarkson, Bayard, McCombie, W. Richard, Kogan, Scott C., Hochhaus, Andreas, Lowe, Scott W.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2006
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1455409/
https://ncbi.nlm.nih.gov/pubmed/16651519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0602402103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados